Who should not receive gadofosveset trisodium injection for IV use?

Gadofosveset trisodium injection for intravenous use should not be administered to people who suffer from the following: arrhythmia; long QT syndrome; liver disease; hemolytic or sickle cell anemia, asthma or respiratory problems; severe acute or chronic renal insufficiency; hepatorenal syndrome; or anyone post-liver transplant. There is an increased risk of developing nephrogenic systemic fibrosis (NSF). Additionally, if you are already receiving dialysis, receiving gadofosveset trisodium may lead to acute renal failure. Gadofosveset should be used cautiously by women who are pregnant or  breastfeeding. It is not known what effect gadofosveset has on a fetus or if it is passed to a nursing infant through breast milk. Children under 18 years of age should not receive gadofosveset, as studies have not been conducted on this subgroup.  

Continue Learning about Diagnostic Agent

Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.